- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Benefit of Prompt Versus Delayed Initiation of Single-Inhaler Triple Therapy on Exacerbations and Healthcare Costs Among Patients with Chronic Obstructive Pulmonary Disease in the US
FDAMA 114: For distribution only to members of payers, formulary committees, or similar entities.
This publication was funded and developed by GSK.
This AJMC® Clinical Brief summarizes a retrospective study by Michael Bogart, PharmD, director of U.S. Value, Evidence, and Outcomes at GSK and colleagues that was presented at the American Thoracic Society 2021 International Conference on May 14, 2021. This article contains key information from the study on how the time to initiation of single-inhaler triple therapy following a first exacerbation can affect rates of subsequent exacerbations and healthcare costs in a large commercially insured population of patients with chronic obstructive pulmonary disease in the United States. The study was funded and developed by GSK.
